| Drug ID: | Drug80 |
|---|---|
| Drug Name: | Curcumin |
| CID: | 969516 |
| DrugBank ID: | DB11672 |
| Modality: | Small Molecule |
| Groups: | NULL |
| US Approved: | NO |
| Other Approved: | NO |
| Identifier: | NCT00889161, , NCT04713631 |
| Molecular Formula: | C21H20O6 |
| Molecular Weight: | 368.4 g/mol |
| Isomeric SMILES: | COC1=C(C=CC(=C1)/C=C/C(=O)CC(=O)/C=C/C2=CC(=C(C=C2)O)OC)O |
| Synonyms: | curcumin; 458-37-7; Diferuloylmethane; Natural yellow 3; Kacha haldi; Indian saffron; Gelbwurz; Haldar; Curcumin I; Souchet |
| Phase 0: | 11 |
| Phase 1: | 38 |
| Phase 2: | 67 |
| Phase 3: | 23 |
| Phase 4: | 14 |
| Description: | NULL |
Molecular Structure
Knowledge Graph
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
|---|---|---|---|---|---|---|---|
| dt675 | 969516 | Curcumin | 4843 | NOS2 | Homo sapiens (human) | None | |
| dt676 | 969516 | Curcumin | 765 | CA6 | Homo sapiens (human) | None | |
| dt677 | 969516 | Curcumin | 1576 | CYP3A4 | Homo sapiens (human) | None | |
| dt678 | 969516 | Curcumin | 4318 | MMP9 | Homo sapiens (human) | None | |
| dt679 | 969516 | Curcumin | 1789 | DNMT3B | Homo sapiens (human) | None | |
| dt680 | 969516 | Curcumin | 1786 | DNMT1 | Homo sapiens (human) | None | |
| dt681 | 969516 | Curcumin | 351 | APP | Homo sapiens (human) | None | |
| dt682 | 969516 | Curcumin | 759 | CA1 | Homo sapiens (human) | None | |
| dt683 | 969516 | Curcumin | 5743 | PTGS2 | Homo sapiens (human) | None | |
| dt684 | 969516 | Curcumin | 5594 | MAPK1 | Rattus norvegicus (Norway rat) | 11981161 | Curcumin inhibits the reaction [tetracaine results in increased phosphorylation of MAPK1 protein] |
- No data available
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| NCT02683759 | Bio-enhanced Curcumin as an Add-on Treatment in Maintaining Remission of Ulcerative Colitis | PHASE3 | UNKNOWN | Asian Institute of Gastroenterology, India | Ulcerative Colitis | DIETARY_SUPPLEMENT: Bio-enhanced Curcumin Soft Ge… | Details |
| NCT02683733 | Bio-enhanced Curcumin as an Add-On Treatment in Mild to Moderate Ulcerative Colitis | PHASE3 | UNKNOWN | Asian Institute of Gastroenterology, India | Ulcerative Colitis | DIETARY_SUPPLEMENT: Bio-enhanced Curcumin Soft Ge… | Details |
| NCT01320436 | Curcumin + Aminosalicylic Acid (5ASA) Versus 5ASA Alone in the Treatment of Mild to Moderate Ulcerative Colitis | PHASE3 | COMPLETED | Sheba Medical Center | Ulcerative Colitis | DIETARY_SUPPLEMENT: Curcumin|DRUG: 5-aminosalicyl… | Details |
| NCT03122613 | Curcumin for Prevention of Relapse in Patients With Ulcerative Colitis | None | TERMINATED | Chinese University of Hong Kong | Ulcerative Colitis in Remission | DIETARY_SUPPLEMENT: Curcumin|DRUG: Placebo | Details |
| NCT04713631 | Safety and Efficacy of Artesunate & Curcumin in Crohn's Disease | PHASE2 | RECRUITING | Sanjay Gandhi Postgraduate Institute of Medical Sciences | Crohn's Disease | DRUG: Artesunate|DRUG: Curcumin|DRUG: Placebo A|D… | Details |
| NCT06867939 | A Pilot Study of Curcumin (Soloways in Patients With Inflammatory Bowel Disease Homozygous for the IL-10 Variant | Not Available | Not recruiting | S.LAB (SOLOWAYS) | Inflamatory Bowel Disease | Dietary Supplement: liposomal curcumin;Dietary Su… | Details |
| RBR-89q4ydz | Effect of supplementation with Curcuma Longa (extract) and Piperine on inflammatory markers, oxidative stress and glycoxidation in patients with Inflammatory Bowel Disease treated at a Teaching Hospital in Alagoa | Not Available | Not Recruiting | Universidade Federal de Alagoas | Inflammatory Bowel Disease | This is a double-blind randomized clinical trial.… | Details |
| NCT04879810 | Pilot Clinical Trial Investigating the Ability of Plant Exosomes +/- Curcumin to Abrogate Symptoms of Inflammatory Bowel Disease (IBD) | Not Available | Not recruiting | University of Louisville | Irritable Bowel Disease | Procedure: Sigmoidoscopy and biopsy, blood work | Details |
| JPRN-UMIN000015770 | Randomized double-blind multicenter study for anti-inflammatory effects of highly bioavailable curcumin on Crohn's disease. - Exploratory study for effects of highly bioavailable curcumin on Crohn's disease. | Not Available | Not Recruiting | Hamamatsu South Hospital, Centre for Gastroenterology and Inflammatory Bowel Disease Research | Crohn's disease (180 <= CDAI < 450) … | Standard therapy for Crohn's disease (Pentasa… | Details |
| NCT00889161 | Curcumin in Pediatric Inflammatory Bowel Disease | PHASE1 | COMPLETED | Seattle Children's Hospital | Inflammatory Bowel Disease|Ulcerative Colitis|Cro… | DRUG: Curcumin | Details |
| NCT05761327 | Investigation of the Effects of Curcumin and Resveratrol Supplements Added to the Mediterranean Diet on Disease Severity and Inflammatory Biomarkers in Patients With Ulcerative Colitis | None | COMPLETED | Ardahan University | Ulcerative Colitis | OTHER: Mediterranean Diet|DIETARY_SUPPLEMENT: Cur… | Details |
| NCT02277223 | Curcumin in Pediatric Ulcerative Colitis | PHASE3 | WITHDRAWN | Schneider Children's Medical Center, Israel | Ulcerative Colitis | DIETARY_SUPPLEMENT: Curcumin|DRUG: Placebo | Details |
| NCT03500653 | Curcumin Supplementation as an Add on Treatment for Patients With Inflammatory Bowel Diseases Treated With Vedolizumab | None | UNKNOWN | Henit Yanai | Inflammatory Bowel Diseases | DIETARY_SUPPLEMENT: Curcumin|DIETARY_SUPPLEMENT: … | Details |
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| 1.0 | Crohn's disease | An intestinal disease that involves inflammation located_in intestine. | disease of anatomical entity gastrointestinal system disease, intestinal disease, inflammatory bowel disease | Obiltoxaximab; Budesonide; Hydrocortisone acetate; Sulfasalazine; Ursodeoxycholic acid; Pegunigalsidase alfa; Imiglucerase; Bictegravir; Taliglucerase alfa; Etelcalcetide; Cimetidine; Desonide | Crohn's disease is a relapsing systemic inflammatory diseas… | Details |
| 2.0 | ulcerative colitis | A colitis that is predominantly confined to the mucosa located_in colon and includes characteristic ulcers, or open sores. | disease of anatomical entity, gastrointestinal system disease, autoimmune disease of gastrointestinal tract; intestinal disease, inflammatory bowel disease, colitis; disease, primary immunodeficiency disease, autoimmune disease, autoimmune disease of gastrointestinal tract | Mirikizumab; Olsalazine; Balsalazide; Sulfasalazine; Budesonide; Hydrocortisone acetate; Tixocortol; Kappadione; Teicoplanin; Atezolizumab; Gamolenic acid; Upadacitinib | No abstract available | Details |
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| S01 | Anti-inflammatory | inflammatory | 5-Aminosalicylates (5-ASAs); corticosteroids | Crohn's disease and ulcerative colitis are the two main com… | Details |
| S02 | Immunosuppression | Classic immunosuppressive drugs | azathioprine; 6-mercaptopurine; methotrexate; ciclosporin-A; tacrolimus | Ciclosporin-A and tacrolimus bind to specific intracellular… | Details |
| S03 | Anti-TNF agents | Tumor necrosis factor | infliximab; adalimumab; golimumab; certolizumab pegol | TNF is produced by various immune and non-immune cells in t… | Details |
| S04 | T-cell homing and retention | T-cell trafficking | vedolizumab; anti-MAdCAM1 antibodies ; etrolizumab | Inhibition of the interaction between α4β7 integrins on T c… | Details |
| S05 | Angiogenesis | cell proliferation; vascular permeability | ozanimod | The bioactive lipid S1P has been shown to activate NF-κB an… | Details |
| S07 | Blockade of cytokine | Cytokine signalling | apremilast; roflumilast; filgotinib; tofacitinib; ABT494; ABT-874; ustekinumab; isankizumab; LY-2525623; AMG139; MEDI2079; guselkumab | Various T-cell subsets, their differentiation pathways and … | Details |
| S08 | Strengthening barrier function | Modulation of barrier function | phosphatidylcholine (lecithin); imiquimod; mongersen | Escherichia coli Nissle (EcN) is a nonpathogenic Gram-negat… | Details |
| S11 | Improveming Intestinal Microecology | the intestinal microbiota | antibiotics; probiotics; prebiotics; postbiotics; synbiotics; fecal microbiota transplantation (FMT) | The imbalance between beneficial bacteria and harmful patho… | Details |
Curcumin in inflammatory diseases
PMID: 23281076
Year: 2013
Relationship Type:
Treatment
Score: 10.0
Curcumin (diferuloylmethane), a yellow coloring agent extracted from turmeric is also used as a remedy for the treatment and prevention of inflammato…
A Randomized Double-Blind, Placebo-Controlled Trial of Artesunate and Curcumin …
PMID: 40589768
Year: 2025
Relationship Type:
Treatment
Score: 9.5
AIM: Less than half of all patients with Crohn's disease remain in remission with long-term use of azathioprine. Our aim was to assess the efficacy o…
Therapeutic and prophylactic role of vitamin D and curcumin in acetic acid-indu…
PMID: 36872571
Year: 2023
Relationship Type:
Treatment
Score: 9.5
Ulcerative Colitis (UC) is a disease that negatively affects quality of life and is associated with sustained oxidative stress, inflammation and inte…
Investigating the Mechanisms of Bisdemethoxycurcumin in Ulcerative Colitis: Net…
PMID: 36615264
Year: 2022
Relationship Type:
Treatment
Score: 9.5
Ulcerative colitis is a chronic inflammatory bowel disorder that is hard to cure once diagnosed. Bisdemethoxycurcumin has shown positive effects on i…
Old but Fancy: Curcumin in Ulcerative Colitis-Current Overview
PMID: 36558408
Year: 2022
Relationship Type:
Treatment
Score: 9.5
Ulcerative colitis (UC) is one of the inflammatory bowel diseases (IBD). It is a chronic autoimmune inflammation of unclear etiology affecting the co…
Review of the Effects and Mechanism of Curcumin in the Treatment of Inflammator…
PMID: 35795556
Year: 2022
Relationship Type:
Treatment
Score: 9.5
Curcumin is extracted from the rhizomes of Curcuma longa L. It is now widely used in food processing, cosmetics, dyes, etc. Current researching indic…
Therapeutic Potential of Curcumin in a Rat Model of Dextran Sulfate Sodium-Indu…
PMID: 35731315
Year: 2022
Relationship Type:
Treatment
Score: 9.5
The pathogenesis of ulcerative colitis (UC) remains unclear, and it is believed that an imbalance of regulatory T (Treg) cells and T helper 17 (Th17)…
Anti-Inflammatory Effects of Curcumin in the Inflammatory Diseases: Status, Lim…
PMID: 34754179
Year: 2021
Relationship Type:
Treatment
Score: 9.5
Curcumin is a natural compound with great potential for disease treatment. A large number of studies have proved that curcumin has a variety of biolo…
Targeting the balance of T helper cell responses by curcumin in inflammatory an…
PMID: 31059845
Year: 2019
Relationship Type:
Association
Score: 9.5
CD4(+) T helper (Th) cells are a crucial player in host defense but under certain conditions can contribute to the pathogenesis of inflammatory and a…
Essential turmeric oils enhance anti-inflammatory efficacy of curcumin in dextr…
PMID: 28400554
Year: 2017
Relationship Type:
Treatment
Score: 9.3
Turmeric has been used as a medicinal herb for thousands of years for treatment of various disorders. Although curcumin is the most studied active co…
Therapeutic potential of curcumin in gastrointestinal diseases
PMID: 21607160
Year: 2011
Relationship Type:
Treatment
Score: 9.1
Curcumin, also known as diferuloylmethane, is derived from the plant Curcuma longa and is the active ingredient of the spice turmeric. The therapeuti…
Treatment of colitis by oral negatively charged nanostructured curcumin in rats
PMID: 35976279
Year: 2022
Relationship Type:
Treatment
Score: 8.5
PURPOSE: To examine the effects of a negatively charged nanostructured curcumin microemulsion in experimental ulcerative colitis (UC) in rats. METHOD…
Enhancing stability and anti-inflammatory properties of curcumin in ulcerative …
PMID: 33744379
Year: 2021
Relationship Type:
Treatment
Score: 8.5
Curcumin liposomes (CUR-LPs) was identified by evaluating morphology, appearance, zeta potential, particle diameter, and drug encapsulation efficienc…
Genipin-crosslinked human serum albumin coating using a tannic acid layer for e…
PMID: 32540526
Year: 2020
Relationship Type:
Treatment
Score: 8.5
Curcumin (CUR) is a promising edible phytochemical compound with ideal ulcerative colitis (UC) treatment activity; however, it is characteristically …
Use of Curcumin in Achieving Clinical and Endoscopic Remission in Ulcerative Co…
PMID: 30360803
Year: 2018
Relationship Type:
Treatment
Score: 8.3
BACKGROUND: Ulcerative Colitis (UC) is characterized by chronic inflammation of the mucosal layers of the colon. Treatment of refractory UC is challe…
Curcumin improves regulatory T cells in gut-associated lymphoid tissue of colit…
PMID: 27340353
Year: 2016
Relationship Type:
Treatment
Score: 8.3
AIM: To explore the probable pathway by which curcumin (Cur) regulates the function of Treg cells by observing the expression of costimulatory molecu…
Curcumin: an orally bioavailable blocker of TNF and other pro-inflammatory biom…
PMID: 23425071
Year: 2013
Relationship Type:
Treatment
Score: 8.1
TNFs are major mediators of inflammation and inflammation-related diseases, hence, the United States Food and Drug Administration (FDA) has approved …
Curcumin for inflammatory bowel disease: a review of human studies
PMID: 21649456
Year: 2011
Relationship Type:
Treatment
Score: 8.1
OBJECTIVE: To evaluate the use of curcumin in inflammatory bowel disease. DATA SOURCES: ALTMEDEX, Comprehensive Database of Natural Medicines, MEDLIN…
Colon-targeted dual-coating MOF nanoparticles for the delivery of curcumin with…
PMID: 39908958
Year: 2025
Relationship Type:
Treatment
Score: 7.5
The inflammatory response is the core mechanism of the pathogenesis and symptoms of ulcerative colitis (UC), and inhibiting inflammation is a promisi…
Curcumin promotes renewal of intestinal epithelium by miR-195-3p
PMID: 37972911
Year: 2024
Relationship Type:
Treatment
Score: 7.5
ETHNOPHARMACOLOGICAL RELEVANCE: Turmeric (Curcuma longa) has been used to treat gastrointestinal disorders in the Indian Ayurvedic medical system. Ac…